These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12898346)

  • 1. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
    Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U
    Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y
    Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
    Nyholm D; Johansson A; Lennernäs H; Askmark H
    Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S; Herrmann L; Salmen S; Müller T
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
    Onofrj M; Thomas A; Iacono D; Di Iorio A; Bonanni L
    Eur Neurol; 2001; 46(1):11-6. PubMed ID: 11455177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COMT inhibition: a new treatment strategy for Parkinson's disease.
    Kurth MC; Adler CH
    Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
    Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
    J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.